Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Pharmaceuticals · 21.08.2025 · 18 (8) · 1235
DOI: 10.3390/ph18081235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.08.2025. Verfasst von Ilaria Cosci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, 35122 Padova, Italy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Current Research” funds from the Italian Ministry of Health.
Abstract (Originalsprache)
Background
Melanoma, the deadliest human skin cancer, frequently harbors activating BRAF mutations, with V600E being the most prevalent. These alterations drive constitutive activation of the MAPK pathway, promoting uncontrolled cell proliferation, survival, and dissemination. The advent of BRAFi and MEKi has significantly improved outcomes in BRAF V600-mutant melanoma. However, therapeutic resistance remains a major clinical barrier.
Methods
This review integrates recent findings from preclinical and clinical studies to delineate resistance mechanisms to BRAF-targeted therapy. It categorizes resistance into primary (intrinsic), adaptive, and acquired forms, and analyzes their molecular underpinnings, including genetic and epigenetic alterations, pathway reactivation, and microenvironmental interactions.
Results
Primary resistance is linked to pre-existing genetic and epigenetic changes that activate alternative signaling pathways, such as PI3K-AKT. Adaptive and acquired resistance includes secondary BRAF mutations, pathway redundancy, phenotype switching, and immune and stromal interactions. High-throughput sequencing has revealed novel mutations, including NRAS, NF1, and PTEN alterations, that contribute to resistance.
Discussion
Understanding the multifaceted nature of resistance is critical to improving outcomes in advanced melanoma. This review highlights emerging strategies to overcome resistance, including combinatorial therapies, metabolic targeting, and biomarker-driven approaches, aiming to inform future therapeutic development and precision oncology strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, 35122 Padova, Italy.
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
- Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.
- Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padova, 35138 Padova, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
ORCID-Profile: Ilaria Cosci, Valentina Salizzato, Paolo Del Fiore, Jacopo Pigozzo, Simone Mocellin, Alberto Ferlin, Sara Mathlouthi, Mariangela Garofalo
Förderung
- “Current Research” funds from the Italian Ministry of Health
Zitieren
APA
Cosci, I., Salizzato, V., Del Fiore, P., Pigozzo, J., Guarneri, V., Mocellin, S., Ferlin, A., Mathlouthi, S., Piccin, L., & Garofalo, M. (2025). Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Pharmaceuticals, 18(8), 1235. https://doi.org/10.3390/ph18081235
Vancouver
Cosci I, Salizzato V, Del Fiore P, Pigozzo J, Guarneri V, Mocellin S, et al. Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Pharmaceuticals. 2025;18(8):1235. doi:10.3390/ph18081235
BibTeX
@article{Cosci2025,
author = {Cosci, Ilaria and Salizzato, Valentina and Del Fiore, Paolo and Pigozzo, Jacopo and Guarneri, Valentina and Mocellin, Simone and Ferlin, Alberto and Mathlouthi, Sara and Piccin, Luisa and Garofalo, Mariangela},
title = {Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1235},
doi = {10.3390/ph18081235}
}
EUVIMED